A detailed history of Balyasny Asset Management LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Balyasny Asset Management LLC holds 5,400 shares of BNTX stock, worth $559,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,400
Previous 455,918 98.82%
Holding current value
$559,224
Previous $36.6 Million 98.25%
% of portfolio
0.0%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.36 - $124.66 $12.9 Million - $20.5 Million
164,548 Added 36.09%
620,466 $73.7 Million
Q2 2024

Aug 14, 2024

BUY
$80.36 - $102.87 $21.4 Million - $27.3 Million
265,816 Added 139.83%
455,918 $36.6 Million
Q1 2024

May 13, 2024

BUY
$88.96 - $112.35 $16.9 Million - $21.4 Million
190,102 New
190,102 $17.5 Million
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $19.2 Million - $24.4 Million
195,104 Added 127.0%
348,728 $37.9 Million
Q2 2023

Aug 14, 2023

BUY
$102.58 - $129.66 $15.8 Million - $19.9 Million
153,624 New
153,624 $16.6 Million
Q4 2022

Feb 14, 2023

BUY
$118.43 - $186.05 $12.5 Million - $19.7 Million
105,691 Added 1348.62%
113,528 $17.1 Million
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $365,589 - $524,427
2,864 Added 57.59%
7,837 $1.06 Million
Q2 2022

Aug 15, 2022

SELL
$123.25 - $186.24 $12.8 Million - $19.3 Million
-103,495 Reduced 95.42%
4,973 $741,000
Q1 2022

May 16, 2022

BUY
$126.25 - $231.85 $13.7 Million - $25.1 Million
108,468 New
108,468 $18.5 Million
Q4 2021

Feb 14, 2022

SELL
$216.64 - $362.52 $8.33 Million - $13.9 Million
-38,455 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$205.93 - $447.23 $29.5 Million - $64 Million
-143,164 Reduced 78.83%
38,455 $10.5 Million
Q3 2020

Nov 16, 2020

SELL
$57.81 - $104.17 $1.98 Million - $3.56 Million
-34,166 Reduced 15.83%
181,619 $12.6 Million
Q2 2020

Aug 14, 2020

BUY
$38.58 - $66.74 $8.32 Million - $14.4 Million
215,785 New
215,785 $14.4 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $25.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.